BACKGROUND: Catheter-related bloodstream infections (BSIs) are a serious problem leading to increased morbidity, longer hospital stay, and hence, additional costs. This study evaluated the risk of BSI and the cost of parenteral nutrition (PN) in Germany. SUBJECTS/METHODS: A retrospective observational chart review of patients hospitalized from October 2009 to April 2011 and receiving PN via ready-to-use three-chamber bag (MCB), single bottle (SB) or hospital compounded admixture (CPN) was conducted across Germany. Propensity score-adjusted models were used to evaluate the association between the type of PN, BSI (Cox Proportional Hazards) and hospitalization cost (generalized linear models) within a subgroup receiving all three macronutrients (lipids, amino acids, glucose). RESULTS: Of the 1995 patient records reviewed (MCB = 816; CPN = 584; SB = 595), 1457 patients received all three macronutrients. After adjustment, SB was associated with an increased hazard of BSI, vs MCB without additions (hazard ratio (HR) (95% confidence interval (CI)) = 2.53 (1.66-3.86)) in the total cohort. Adding supplements to MCB on the ward also increased the BSI risk in both total and subgroup analyses. In patients receiving all three macronutrients, adjusted total costs were MCB (no additions): €6,572 (95% CI: €6,896-6263); CPN: €6,869 (€7,283-6479); SB: €6,872 (€7,242-6521); MCB (ward additions): €7,402 (€7,878-6955); P o 0.001; Po 0.001. CONCLUSION: Use of MCB does not appear to increase treatment costs, possibly by reducing the risk of infection. This study identified several PN preparation methods associated with a significantly increased hazard for BSI; definitive CPN findings are limited by our inability to distinguish automated from manual pharmacy compounding.
INTRODUCTION
Parenteral nutrition (PN) is a life-saving therapy for patients with intestinal failure and may be critically important for trauma patients, those with inflammatory bowel disease, gastrointestinal fistulae, pancreatitis, pre-term infants and patients being treated for certain types of cancer. 1 However, safety concerns surround the use of PN and the risk for bloodstream infection (BSI). Catheter-related BSIs are a serious problem occurring at an average rate of 5 per 1000 catheter days in the United States.
2 BSI leads to increased morbidity, longer length of hospital stay and additional cost of care. Prior studies have demonstrated higher BSI rates in patients receiving PN than for similar non-PN cohorts. It is estimated that the rate of BSI in PN patients is 1.3-39%, depending on patient characteristics and site of care. [3] [4] [5] [6] [7] The limited research available in the area of BSI and PN use indicates that delivery system (for example, multi-chamber bag, compounded, etc.) may impact the risk of BSI. Retrospective analyses with large claim databases indicate that PN delivered via multi-chamber bags (a low-risk system per established standards for Good Compounding Practices by USP Chapter o 797>, Pharmaceutical Compounding: Sterile Preparations 8 ) is associated with fewer BSIs than compounded PN of several vials into a final solution (a medium to high-risk system). Multi-chamber, pre-mixed PN solutions are the standard of care in developed countries, 9 and have been associated with lower infection rates and shorter infection-attributable length of stay and lower costs. 10 This study sought to determine the hazard of BSI associated with PN delivered by ready-to-use three-chamber bag (MCB), hospital compounded admixture (CPN) or single bottles (SBs) in Germany. The daily mean cost of PN for each method and total hospital episode costs were also examined.
METHODS

A REtrospective ObservatioNal Study of TREatment Patterns and REsource
UtilizatioN of ParentEral NUtrition in GeRmany (ENTREPENEUR) was conducted of in patients hospitalized from October 2009 to April 2011 across Germany using patient medical records as the primary source document. A representative quota sample of hospital-based physicians (n = 58) representing 39 diverse institutions were recruited from a national database. Physicians were randomly selected from a national hospital database that was sourced from the German Federal Statistics Office. This physician database, containing approximately 1500 physicians, was used to recruit eligible physicians. Using this database, random physician identification numbers, for example, the 4th, 15th, 24th, 25th, etc., were generated to screen physicians for study eligibility. The eligible and recruited physicians acted as study investigators and were responsible for patient selection and chart data abstraction following instructions from the contract research organization (Medical Data Analytics).
Investigator and patient selection Study investigators included specialties such as general surgery, critical care, gastroenterology, oncology, anesthesiology and internal medicine. Investigators were supplied with a study protocol outlining study rules and guidelines for data abstraction, patient selection and study administrator contact information. Investigators were included in the study if they had more than 2 years, but less than 30 years of practice after completion of training, spent >50% of their working time performing direct patient care, managed more than 20 patients with at least 4 days of hospitalization in the past 12 months, and had access to complete medical chart information for selected patients.
Study investigators were provided with patient selection criteria using patient birth month as a criteria for patient selection among those patients qualifying for the study to ensure representativeness of the sample. Investigators randomly selected patient charts from their practice to review, which met the following criteria;
• Patients were at least 18 years of age • Received PN for any condition, including intestinal failure or GI conditions (for example, severe short bowel syndrome, severe radiation enteritis, trauma, pancreatitis) for ⩾ 4 days • Adult patients hospitalized within the past 12 months for any conditions requiring PN administration • PN delivered through MCB, SB or CPN • Patients with complete medical record inclusive of treatment information, PN administration details and adverse events.
Clinical data were collected using field-tested physician profile forms and cohort-specific case report forms (CRFs). Data validations occurred in a random sample of CRFs, with every field in the selected form validated against the source document. Any instance of missing data was documented and resolved with the originating investigator. Key variables collected included patient demographics, reason for hospitalization, duration of hospitalization, discharge status, PN (duration, type, components and route of administration), complications (BSIs, metabolic events and other complications), surgical procedures and catheter placements. MDA, the contract research organization, conducted the data validations. Specifically, a random sample of at least 30% of the completed CRFs was validated using the medical record as the source document.
This study was conducted in accordance with International Society for Pharmacoepidemiology Guidelines for Good Epidemiology Practices and all applicable regulatory requirements. 11 As a retrospective chart review study, no personal patient identifiers were collected. Informed consent was not required from individual patients under internal review board exemption status. Study investigators, who provided data from their own hospital, followed their internal institution requirements for ethics review. The identity of each investigator and their hospital were anonymous to the study sponsor.
Cohorts and subgroups
Multi-chamber bags contained all three macronutrients (fats, carbohydrates, protein); therefore the primary cohort for analysis was the subgroup of patients who received PN containing lipids, amino acids and glucose. We have also provided results for the full cohort of patients, including those who received any investigator-reported PN, regardless of whether it contained any or all three macronutrients.
Results were compared across PN preparation methods: MCB, CPN and SB. MCB patients were further divided into MCB with ward additions (MCB (ward additions)) or MCB with either no additions or with additions made in the pharmacy (MCB (no ward additions)). Additions made in the pharmacy were grouped with the no ward additions subgroup because this practice is consistent with clinical guidelines. 12 
Outcomes
Blood stream infections. BSIs were measured according to physician report within the CRF. Based on documentation in the patients' charts, physicians recorded in the CRF whether or not patients' experienced a BSI while in the hospital and treatment. When patients had more than one BSI identified, date of the first BSI was recorded. Time to BSI was calculated by indexing patients on the date of their hospital admission and calculating the number of days until the BSI developed.
Costs outcomes. Total costs were calculated as a sum of costs per bed day, PN macronutrient costs (lipids, amino acids, glucose) and labor costs associated with PN. Bed day costs were assumed to be €410.7 using published sources. 13 Cost of PN was determined by multiplying the cost per ml for individual PN components by the volume of the component used per day, 14 then multiplied by the number of days using that component. For PN components that were write-ins, or in cases when costs were not available, the mean macronutrient cost (for example, amino acids, glucose and lipid) was used. It was assumed that all glucose solutions contained 20% glucose. Labor costs were assumed at €8 daily for SB and CMP and €2.44 daily for MCB administration with and without additions. 15 When patients' discharge date was not recorded (n = 12), last date of PN was used as a proxy to measure the number of bed days. All costs were adjusted using Eurostat to 2011 Euros. 16 
Statistical analysis
All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA), with cross-tabulations performed using Wincross software (The Analytical Group, Inc., Scottsdale, AZ, USA).
Univariate and bivariate comparisons. Descriptive univariate and bivariate comparisons across types of PN were calculated for patient clinical and demographic characteristics, using χ 2 -tests to test for differences in categorical and analysis of variance for differences in continuous variables. Unless otherwise stated, two-sided significance tests were used with Po0.05 indicating statistical significance. Analyses were conducted on the total population and a subgroup of patients receiving all three macronutrients.
Propensity score calculation. As there may have been systematic differences by the type of PN preparation delivery system received with regards to clinical/demographic characteristics, or differences between hospitals that had certain products on formulary, propensity scores were used to reduce any selection bias and confounding of indication. 17 Propensity scores included variables for employment status, type of admission (emergency vs elective admission), reason for hospitalization (neoplasm, abnormal clinical finding, blood disorder, circulatory, endocrine, infectious/parasitic, skin disorder), surgery, catheter placement, hospital type (community, teaching, university), physician specialty (general surgeon, gastroenterology, oncology), age at admission and length of stay before PN and used multinomial logistic regression. Propensity scores referencing probability of receiving MCB (no additions) were used within analyses as a covariate within multivariable models.
Multivariate models. Cox proportional hazard models were used to evaluate days to BSI associated with PN formulation, referencing MCB (no ward additions). Models were adjusted for the propensity to receive MCB without additions, antibiotics use before infection (had to be initiated at least 3 days before infection, as in use immediately before or following BSI would be treatment for BSI) and time-dependent variables for central venous catheter use and PN initiation. If a patient had multiple BSI instances, we only measured time to the first infection. Propensity scores included age, gender, BMI, employment status (employed, unemployed), admission type (emergency, elective, transfer), type of hospital (university, teaching or general), reason for hospitalization, length of stay before start of PN, whether enteral nutrition (EN) was also received, whether the patient also underwent surgeries or were catheterized, and type of physician treating the patient.
Generalized linear models with gamma distribution and log link were used to provide cost estimates, adjusting for propensity score and proportion of nutrition received via PN versus EN. Least square means adjusted cost estimates were calculated for each PN preparation method, using mean values for all other covariates. Cost analyses were only performed within the subgroup of patients receiving all three macronutrients.
RESULTS
The study included a representative quota sample of 58 hospitalbased medical doctors in Germany. Oncology was the reported specialty for 17 investigators, internal medicine (10), critical care/ intensive care specialists (10), gastroenterology/gastroenterology surgeons (10), neonatologists/pediatricians (6), anesthesiologists (3) and general surgeons (2) . Baseline demographics for the entire cohort are presented in Table 1 . Patient data were abstracted from 1995 patient medical records (MCB = 816; CPN = 584; SB = 595), of which, 1457 patients were treated with PN including lipids, amino acids and glucose (MCB = 816; CPN = 364; SB = 277). Within the full cohort, 45.5% of patients were treated in teaching, 30.1% in university and 24.3% in community hospitals per physician reports (Table 1) .
Data were included from 1017 male and 978 female patients, with an average 61.7 years of age. Seventy percent of patients who received PN were admitted to the hospital on an emergency basis. Fifty percent had an admission diagnosis of neoplasm and the other half had primary diagnoses spanning across digestion, respiratory, circulation, infections and metabolic diseases. In 89% of admissions, a concomitant condition was listed. Malignancy was the most common secondary condition, occurring in 44% of admissions. Demographic characteristics were similar for those patients who received PN with all three macronutrients (Supplementary Table 1 Propensity scores Based on multinomial logistic regression, as compared with patients who received MCB without ward additions, CPN patients were younger, more likely to be unemployed, have an non-emergency admission, without surgeries, have had a catheter placed while inpatient, and been treated by an intensive care physician. MCB with ward addition (as compared with without additions) patients were more likely to be younger, unemployed, had a non-emergency admission, be also receiving EN, have had a catheter placed while inpatient and be treated by a gastroenterologist and/or intensive care physician. SB patients were more likely to be receiving concomitant EN, have had a catheter placed while inpatient, and had a shorter length of stay before the start of PN. In addition, SB and MCB patients were more likely to be admitted for non-neoplastic reasons.
BSIs
Within the full cohort, 12% of PN patients experienced a complication during their hospitalization. BSIs were the most common complication, of which 89% were bacterial and 7% fungal. In a subset of 6% patients who underwent surgery, 32% of patients experienced a post-operative infection, of which 59% were documented as surgical infectious complications. The rate of BSI per 1000 PN days was 4.3 for MCB without ward additions, 3.7 for CPN, 8.5 for MCB with ward additions and 9.1 for SB.
After adjustment for propensity to receive MCB without additions, antibiotics use prior to central venous catheter use and PN initiation, Cox proportional hazards model results (Table 2) indicated that SB was significantly associated with an increased hazard of BSI compared with MCB without additions (HR = 2.53, 95% CI = 1.66-3.86) within the full cohort. Adding supplements to MCB on the ward also significantly increased the risk of BSI (HR = 1.85, 95% CI = 1.17-2.94), when compared with MCB without additions. In the subgroup of patients who received all three macronutrients, both SB and CPN were significantly associated with an increased hazard (HR = 2.46, 95% CI = 1.53-3.96; and HR = 1.84, 95% CI = 1.03-3.27, respectfully) as compared with MCB without ward additions. Once again, MCB with ward additions was associated with significantly increased hazard for BSI (HR = 1.87, 95% CI = 1.18-2.97). 
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Costs After adjustment, total costs were comparable for patients taking PN without ward additions, SB and CPN, but were 9% higher in MCB with ward additions as compared with without additions (P = 0.026; Table 3 ). Costs were driven largely by bed day costs, which were statistically similar between PN delivery systems and lowest for MCB (no ward additions), and PN costs, which were 27% higher for MCB with ward additions. Although labor costs for PN preparation did account for o 1% of total costs, they were significantly higher for patients treated with SB and CPN as compared with MCB (with and without additions, P o0.001).
When PN costs were converted to daily costs, SB and CPN had significantly lower costs as compared with MCB (no ward additions; Po 0.001) after adjustment for propensity score and proportion of nutrition received via PN versus EN.
DISCUSSION
The ENTREPRENEUR study sought to determine the risk for BSI associated with PN, and results demonstrate that there are some PN practices associated with an increased hazard for BSI. Our data indicate that for patients who received PN via MCB, additional PN components were generally added in the ward, and not under aseptic conditions in the hospital pharmacy. This practice was associated with an increase in the incidence of BSI. Both SB and compounded PN were associated with a significant increase in BSIs, compared with MCB without additions or when additions to the MCB were made in the hospital pharmacy. Catheter-related BSI is a health-care-associated event with increased mortality and costs. Efforts to reduce BSI have demonstrated success in both reducing costs and enhancing patient safety. Johns Hopkins Quality and Safety Research Group demonstrated in 103 intensive care units in Michigan, USA, that evidence-based infection control interventions, along with an improved culture of patient safety can reduce central lineassociated BSIs (CLABSIs) by 60%, resulting in an estimated USD200 million and 2000 lives saved. 11, 18 The World Health Organization worked with the Hopkins team to expand this study to England and Spain. The Spanish project, called Bacteremia-zero, reduced CLABSI by 50% in 192 intensive care units between 2008 and 2010. 19 The International Nosocomial Infection Control Consortium (INICC) was established in 2002 in 15 developing countries to reduce health-care-associated infections. INICC has been successful in reducing CLABSI incidence by 54% and mortality by 58% by increasing use of infection control and prevention measures. Seven organizations such as the Johns Hopkins Group and the INICC have increased understanding of the preventability of CLABSI, leading to a heightened focus on 'zero tolerability' for hospital-acquired infections and CLABSI.
Additional efforts have been made to encourage good PN practices. German guidelines, in particular, restrict admixing on hospital wards; 10 yet in ENTREPRENEUR additions were made on the ward to 32% of MCB PN solutions. Other organizations, such as the American Society of Health-System Pharmacists (ASHP), emphasize the use of automated compounding devices rather Outcomes in hospitalized patients receiving PN RS Turpin et al than manual compounding to improve patient safety, enhance efficiency and reduce wastage and costs. 20 Our findings are consistent with prior studies. Using a large retrospective data, Turpin and colleagues found that adult patients who received MCB had significantly lower risk of BSI compared with those who received pharmacy-prepared PN (19.6% vs 25.9%, P o 0.001). 21 Using the same data, Pontes-Arruda et al. conducted a similar comparison among a subgroup of intensive care unit patients and found that the risk of BSI was 19% higher when using pharmacy and outsourced compounded PN vs MCB PN (29.6% vs 24.9%; odds ratio = 1.29; 95% CI = 1.06-1.59). 22 Economically, once product and labor costs were taken into account, the mean daily costs for MCB, SB and CPN were equivalent, although total costs were significantly higher for the MCB when additions were made on the ward. In another study, patients receiving MCB incurred lower health-care costs compared with the compounded PN group. 23 Given the retrospective design of this study, we were only able to assess variables that were included within the patient's medical chart and on our CRFs. Therefore, if patients received central line catheter placement before their admission, their central line catheter was undocumented. In addition, there may be unmeasured confounders of the relationship between catheterization and BSI. For patients not discharged at the time of data collection, we had to use the last recorded day of PN as a proxy for length of stay. For compounding, the method of compounding (whether automated or manual) was not identified in this study. 11 Moreover, infections were identified by physician investigators per existing documentation in the patients' charts, and we did not require independent laboratory confirmation nor specify BSI identification diagnosis codes. Last, it was not collected whether catheter lines were used for blood draws or used for infusions of other drugs or solutions. The impact of other uses with the central lines is unknown on the observed infection rates for both groups.
CONCLUSIONS
Use of MCB does not appear to increase treatment costs, possibly by reducing the risk of infection. The findings from this study support guidelines and several important 'good practices' initiatives for PN preparation and administration. Use of SBs was strongly associated with an increased risk of infection, both for the total group and the subgroup analysis. A change in this practice alone may be associated with significant reduction in infections for patients who require PN. Second, adding PN components on the ward was significantly associated with an increased risk of infection. Of the 560 patients who received PN via MCB, 266 of these cases had additions made on the ward in non-aseptic conditions. This situation represents an important opportunity to improve best practices. Finally, compared with use of MCB prepared under aseptic conditions, compounding PN was associated with greater risk of infection for the subgroup that received PN containing all three macronutrients. Among patients who received all three macronutrients, total costs were significantly higher for patients who received their PN via MCB with ward additions. Use of ready-to-use bags, along with safer practices when making additions to MCB, may represent important support for identifying PN 'best practices,' minimizing the risk for BSI as well as costs. Although this retrospective database analysis has limitations, an important value is the ability to reflect the real-world impact of PN practices.
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